The company is looking for partners to expand commercialization of the therapy around the globe.
Biocon's Kiran Mazumdar-Shaw has been one of the leaders in India attempting to build a biotech community capable of developing drugs for worldwide markets. Now the company has a test case on its hands.
Bolstered by a fresh blast of positive new data on its insulin program and growing profits, India's Biocon today also won a big financial backer for its R&D outsourcing arm as it prepares to take the unit public.
India's Biocon cut the ribbon on a new biologics R&D complex that will host a multi-disciplinary group of more than 300 scientists developing a new generation of "affordable" biologics.
The high-profile CEO of India's Biocon says that she's closing in on a big-name pharma partner for the company's oral insulin program. Kiran Mazumdar-Shaw told Reuters that "we are in advanced
The chairperson of India's Biocon, the always outspoken Kiran Mazumdar-Shaw, has outlined some new steps aimed at keeping the biotech's growth rate roaring along at breakneck speed. She told